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Abstract 
Aims: To identify early clinical, modifiable risk factors for preeclampsia present at first antenatal 
visit and assess the prevalence of pregnancy-related hypertensive disorders in women with pre-
existing diabetes treated with tight glycemic and blood pressure (BP) control.  
Methods: A population-based cohort study of 494 women with pre-existing diabetes (307 and 187 
women with type 1 and type 2 diabetes, respectively), included at their first antenatal visit from 
2012-16. The prevalence of chronic hypertension (without diabetic nephropathy or 
microalbuminuria), gestational hypertension and preeclampsia was recorded. Diabetic 
microangiopathy included presence of nephropathy, microalbuminuria and/or retinopathy. 
Treatment target was BP <135/85 mmHg. 
Results: HbA1c was 6.9±2.4% (50±12 mmol/mol) at first antenatal visit and 6.0±0.6% (43±6 
mmol/mol) before delivery with no differences between women with type 1 and type 2 diabetes. At 
the first antenatal visit, the prevalence of microalbuminuria was 6% (6% vs. 6%), nephropathy 2% 
(1% vs. 2%) and chronic hypertension 6% (3% vs. 10%, p=0.03). Gestational hypertension 
developed in 8% (9% vs. 6%) and preeclampsia developed in 8% (9% vs. 7%). Presence of diabetic 
microangiopathy (adjusted odds ratio (OR) 4.35 (confidence interval 2.12-8.93)) and diastolic BP 
(adjusted OR 1.72 per 10 mmHg (1.05 - 2.82)) at the first antenatal visit were independent risk 
factors for preeclampsia.  
Conclusions: At the first antenatal visit, diastolic BP was the only independent, potentially 
modifiable risk factor for preeclampsia in women with pre-existing diabetes in the context of tight 
glycemic and BP control. One out of four women had hypertensive disorders during pregnancy.  
Keywords: Pre-existing diabetes; pregnancy; preeclampsia; blood pressure; risk factors; prevalence. 
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1. Introduction 
Pregnancy-related hypertensive disorders, including preeclampsia, are leading causes of maternal 
and fetal morbidity and mortality worldwide [1-3]. Four out of ten women with pre-existing 
diabetes are diagnosed with a hypertensive disorder during pregnancy [2, 4]. Hypertension may lead 
to preeclampsia, characterized by hypertension and proteinuria after 20 gestational weeks. In 
women with type 1 diabetes a recent review reported a 17% prevalence of preeclampsia [5].  
In women with type 1 diabetes, the following factors are associated with an increased risk of 
developing preeclampsia: long duration of diabetes, nulliparity, obesity, diabetic kidney 
involvement (diabetic nephropathy or microalbuminuria), elevated BP before pregnancy, 
retinopathy and poor glycemic control [5-8]. Risk factors for preeclampsia in women with type 2 
diabetes are less well documented [6, 7].   
Pathophysiological studies have demonstrated that a high BP [9], elevated urinary albumin 
excretion [9], endothelial dysfunction, increased activation of the renin-angiotensin system and 
markers of cardiac overload are often present in early pregnancy in women with pre-existing 
diabetes who develop preeclampsia [10-14]. All these factors can theoretically be altered by 
antihypertensive treatment, which suggests that tight antihypertensive treatment might be beneficial 
in women with pre-existing diabetes in order to prevent preeclampsia. 
Outside pregnancy, early and intensive antihypertensive treatment is the gold standard treatment to 
prevent development and progression of hypertension and albuminuria in women with pre-existing 
diabetes [15, 16]. A cohort study from our Center have previously documented that BP often 
increases several weeks before clinical presentation of preeclampsia is present in women with pre-
existing diabetes and diabetic kidney involvement [9] and that early antihypertensive treatment  
prevents preterm delivery [15, 17, 18]. Early intervention with antihypertensive treatment may also 
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benefit the remaining women with pre-existing diabetes. Therefore antihypertensive treatment is, at 
our Center, recommended to women with pre-existing diabetes and systolic BP ≥ 135 mmHg and/or 
diastolic BP ≥ 85 mmHg and/or urinary albumin-to-creatinine ratio (ACR)  ≥ 300 mg/g - the so 
called ‘Copenhagen antihypertensive treatment strategy’. 
In the current study we aim to identify early clinical, potentially modifiable risk factors for 
preeclampsia and to assess the prevalence of pregnancy-related hypertensive disorders in women 
with pre-existing diabetes in the context of tight glycemic and BP control.  
2. Subjects, Materials and Methods 
2.1 Study population 
This population-based cohort study includes all consecutive singleton pregnancies in women with 
pre-existing diabetes, giving birth after 22 gestational weeks, between January 2012 and August 
2016, at the Center for Pregnant Women with Diabetes, Rigshospitalet, Denmark. The Center is a 
specialized unit that manages pregnant women with pre-existing diabetes originating from a 
geographically well-defined region of approximately 2.6 million inhabitants.  
Data on 584 women with pre-existing diabetes were recorded. Exclusion criteria were: previous 
bariatric surgery (n=7) and severe concomitant illness (n=22) that could possibly bias the study 
aims. If a woman had more than one pregnancy in the study period (n=61), only the first pregnancy 
was included.  
In total, 307 women with type 1 diabetes and 187 women with type 2 diabetes were included, with 
most (86%) of the women attending the Center before 14 gestational weeks. 
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2.2 Routine diabetes and pregnancy care 
All women followed the routine diabetes and pregnancy care program for pregnant women with 
pre-existing diabetes as previously described in detail [19].  
The women attended obstetric visits at 8, 12, 20, 27, 33, 36 gestational weeks where weight, office 
BP and HbA1c were registered and a sterile urine dipstick was screened for protein [19]. The 
women consulted a diabetes specialist approximately every 1-2 weeks throughout pregnancy, either 
at our Center or at their local diabetes clinic.  
 
2.3 Diet and gestational weight gain recommendations 
At the first antenatal visit, all women received a one-hour dietary consultation with individual 
dietary planning. A low glycemic index diet was recommended according to national guidelines on 
diabetes diet with focus on gestational weight gain defined as the difference between the weight at 
last antenatal visit and the self-reported pre-pregnancy weight [20]. The following gestational 
weight gain targets were recommended [19]: women with pre-pregnancy BMI < 30 kg/m2 were 
recommended to gain 10–15 kg, whereas women with pre-pregnancy BMI ≥ 30 kg/m2 were advised 
to limit their gestational weight gain to 0–5 kg, according to local guidelines [21]. In January 2013 
the use of carbohydrate counting was implemented and the recommendation on total gestational 
weight gain in overweight women (pre-pregnancy BMI 25.0-29.9 kg/m2) was changed to 5-8 kg 
[22]. In an attempt to obtain better compliance, a goal for weekly weight gain was also 
recommended [22].  
 
2.4 Glycemic control 
Throughout pregnancy, the women were advised to measure self-monitored plasma glucose before 
and 90 min after each main meal and at bedtime to obtain plasma glucose values of 4.0– 6.0 mmol/l 
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preprandially and 4.0– 8.0 mmol/l postprandially [19]. The targets for HbA1c were < 6.5% (48 
mmol/mol) before 20 gestational weeks and < 5.6% (38 mmol/mol) after 20 gestational weeks [23]. 
In 2013 the targets for HbA1c were changed to < 6.7% (50 mmol/mol) before 20 gestational weeks 
and < 5.8% (40 mmol/mol) after 20 gestational weeks. In women with type 2 diabetes oral 
hypoglycemic agents were discontinued at the first antenatal visit and insulin was given if needed 
[22].  
 
2.5 The Copenhagen antihypertensive treatment strategy 
The aim of the Copenhagen antihypertensive treatment strategy is to identify and treat hypertension 
in pregnant women with pre-existing diabetes. In addition to those women meeting the ‘typical’ 
definition of hypertension (systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg, based on two 
measurements at least 4 hours apart) [24], women with any of the following characteristics during 
pregnancy:  systolic BP ≥ 135 or diastolic BP ≥ 85 mmHg or ACR ≥ 300 mg/g were also 
recommended treatment with antihypertensive agents, in the present cohort [18]. Antihypertensive 
treatment was titrated to achieve the dual therapeutic goals of (1) reducing BP to < 135/85 mmHg 
and (2) reducing ACR to < 300 mg/g.  Methyldopa was the primary antihypertensive agent used, 
with labetalol and slow-release nifedipine added when necessary. 
 
2.6 Prophylactic aspirin treatment 
Aspirin (75 mg) was recommended daily from 10-12 gestational weeks to one week before 
expected delivery to women with an additional high risk of developing preeclampsia i.e. 
preeclampsia in a previous pregnancy, diabetic nephropathy, microalbuminuria or chronic 
hypertension.  
 
  
 
7 
 
2.7 Data collection 
At the first antenatal visit the following variables were recorded in the local quality assessment 
database, Clinical Measure System (CMS): ethnicity, smoking, self-reported pre-pregnancy weight, 
height, parity, duration of diabetes, presence of nephropathy and/or retinopathy, use of other 
medication and folic acid intake before pregnancy. At the first and last antenatal visit HbA1c, BP, 
weight, daily insulin dose and albuminuria were recorded. The use and type of antihypertensive 
agents before and/or during pregnancy were recorded.  
The following data on perinatal outcome were recorded: preeclampsia, miscarriage, induced 
abortion, delivery mode, preterm delivery, gestational age at delivery, sex and offspring birth 
weight. 
 
2.8 Definitions of diabetes and diabetes complications 
Type 2 diabetes was defined as type 2 diabetes diagnosed before pregnancy or HbA1c ≥ 6.5% (48 
mmol/mol) before 20 gestational weeks [25].  
Retinopathy was defined as presence of any diabetic retinopathy in early pregnancy.  
Microalbuminuria was defined as ACR of 30–300 mg/g and diabetic nephropathy as ACR > 300 
mg/g, based on two urine samples at the first antenatal visit [15], regardless of antihypertensive 
agents, if any. 
Diabetic kidney involvement was defined as presence of diabetic nephropathy or microalbuminuria 
at the first antenatal visit with or without chronic hypertension.  
Diabetic microangiopathy was defined as diabetic kidney involvement and/or retinopathy. 
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2.9 Definition and grouping of pregnancy-related hypertensive disorders 
Office BP was measured with the women seated and after approximately 5 minutes of rest.  
Hypertension was defined as systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg measured at 
least twice with a minimum of four hours between.  
In early pregnancy the women were described as normotensive, having chronic hypertension or 
diabetic kidney involvement. 
Normotension was defined as systolic BP < 140 and diastolic BP < 90 mmHg without diabetic 
kidney involvement.  
Chronic hypertension was defined as hypertension (systolic BP ≥ 140 and/or diastolic BP ≥ 90 
mmHg) diagnosed before 20 gestational weeks without diabetic kidney involvement.  
At the end of pregnancy, women were grouped according to the following four BP groups 
regardless of presence of kidney involvement:  
1) Persistent normotension throughout pregnancy  
2) Persistent chronic hypertension throughout pregnancy without progression to preeclampsia 
[24]  
3) Gestational hypertension defined as de novo hypertension diagnosed after 20 gestational 
weeks without meeting the criteria for preeclampsia [24] 
4) Preeclampsia defined as hypertension after 20 gestational weeks and the coexistence of 
proteinuria, defined as ≥ +1 on a sterile urine dipstick [18]. If diabetic kidney involvement 
was present in early pregnancy a sudden increase of ≥ 15 % in systolic BP or diastolic BP 
was also required. 
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Data on diabetic kidney involvement, retinopathy, chronic hypertension, gestational hypertension 
and preeclampsia were obtained from the CMS database and were further validated by cross 
checking with the Obstetric Database of the Capital Region of Denmark  and the original medical 
records. In case of discrepancy between the data sources, the diagnoses were reviewed by the senior 
endocrinologist (E.R.M.) and senior obstetrician (P.D.).  
 
2.10 Definitions of neonatal outcomes 
Preterm delivery was defined as birth before 37 completed gestational weeks [19]. Birth weight 
standard deviation score (SD-score) was used to describe how far the offspring birth weight was 
from the mean of the national standard population adjusted for gestational age and sex (given as 
SD-units) [26]. Large- and small-for-gestational age (LGA and SGA, respectively) infants were 
defined as offspring birth weight ≥ 90th or ≤ 10th percentile adjusted for gestational age and sex [26].   
 
2.11 Statistical analysis and ethics 
Continuous variables are given as mean (± SD) or median (range), whereas categorical variables are 
given as numbers (%). Women with type 1 and type 2 diabetes were analyzed together and 
separately, as appropriate.  
An independent t-test or Mann-Whitney test for nonparametric testing were used for continuous 
variables and a Chi-square test for categorical variables when comparing women with type 1 and 
type 2 diabetes.  
The four BP groups at the end of pregnancy were compared by one way analysis of variance 
(ANOVA), the Kruskal Wallis test and Chi-square test as appropriate. If significance was found by 
these tests pairwise comparisons between women who developed preeclampsia and women with 
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persistent normotension, persistent chronic hypertension or gestational hypertension, respectively, 
were performed.  Correction for multiple testing was performed using the Bonferroni method 
resulting in a significance level of 0.05/3=0.017, thus a two-sided p-value <0.017 was considered 
significant when comparing the four BP groups at the end of pregnancy.  
Univariate logistic regression analysis was undertaken to explore the association between 
preeclampsia and each of the following variables, selected based on the literature [5-7] : type 1 
diabetes (yes/no); duration of diabetes (years); pre-pregnancy BMI (kg/m2); HbA1c at first visit 
(%); systolic BP and diastolic BP at first visit (mmHg); nulliparity (yes/no); chronic hypertension at 
first visit (yes/no); retinopathy at first visit (yes/no), diabetic kidney involvement (yes/no), 
microangiopathy (yes/no) and preeclampsia (yes/no). To identify possible early risk factors for 
preeclampsia, multivariate logistic regression analysis was applied with preeclampsia as the 
dependent variable and the following four independent variables based on the results of the 
univariate analyses: nulliparity (yes/no), diabetic microangiopathy (yes/no), systolic BP and 
diastolic BP at first visit (per 10 mmHg). Logistic regression analyses were applied to the total 
cohort of women.  
The statistical analyses were made using IBM SPSS statistics 22 (SPSS, Chicago, IL, USA). A two-
sided p-value <0.05 was considered significant, with correction for multiple comparisons as noted 
above. Missing data are reported below each table. 
Approval from the Danish Data Protection Agency and The Danish Health Authority was obtained. 
Approval from the local Ethic committee was not required, according to Danish law. 
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3. Results  
In total, 494 women with pre-existing diabetes were included (Table 1 and Table 2). HbA1c levels 
at the first antenatal visit were 6.9±2.4% (50±12 mmol/mol) and 6.0±0.6% (43±6 mmol/mol) at the 
last antenatal visit before delivery, and were comparable between women with type 1 and type 2 
diabetes (Table 1 and 2).  
At the first antenatal visit, 86% of the 494 women with type 1 and type 2 diabetes were 
normotensive, whereas 6% had chronic hypertension and 8% had diabetic kidney involvement. The 
prevalence of diabetic kidney involvement at the first antenatal visit was comparable between 
women with type 1 and type 2 diabetes (Table 1), while women with type 2 diabetes had a higher 
prevalence of chronic hypertension at the first antenatal visit (3% vs. 10%, p=0.03).  
The overall prevalence of pregnancy-related hypertensive disorders was 23% in both women with 
type 1 and type 2 diabetes. Gestational hypertension developed in 8% of the women while 8% 
developed preeclampsia, with similar prevalence in the two types of diabetes (Table 2).  
Among the women who were normotensive at the first antenatal visit, 6% developed preeclampsia. 
For those with diabetic kidney involvement or chronic hypertension at the first antenatal visit 34% 
and 11% developed preeclampsia, respectively. 
Based on similar prevalence of pregnancy-related hypertensive disorders and diabetic kidney 
involvement in women with type 1 and type 2 diabetes, all women with pre-existing diabetes were 
combined in the following analysis. In total, 40 women developed preeclampsia at median 254 days 
(181-272) and delivered 8 (0-40) days later. Twenty percent of the women who developed 
preeclampsia did so before 34 gestational weeks, 65% between 34 and 37 gestational weeks and 
15% after 37 gestational weeks.  Among the women who developed preeclampsia 60% were 
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normotensive, 32% had diabetic kidney involvement and 8% had chronic hypertension at the first 
antenatal visit. Compared to women remaining normotensive throughout pregnancy, women who 
developed preeclampsia had a higher prevalence of retinopathy and diabetic kidney involvement at 
the first antenatal visit (Table 3).  
The majority of the women with pregnancy-related hypertension were given antihypertensive 
treatment during pregnancy.  Only two normotensive women received antihypertensive treatment 
due to elevated albumin excretion (Table 3).  
Among the 40 women who developed preeclampsia antihypertensive treatment was initiated at 
median 232 days (0-273) in 33 of the women. The time from onset of antihypertensive treatment to 
delivery in women who developed preeclampsia was median 23 days (range 2-259). In the 
remaining seven women induction of labor or cesarean delivery was decided within one to two days 
after the diagnosis of preeclampsia and antihypertensive treatment was not initiated.  
The mean systolic BP was 143±13 mmHg and the mean diastolic BP was 91±9 mmHg when 
antihypertensive treatment was initiated during pregnancy and in 90% of the cases hypertension 
was diagnosed with systolic BP ≥ 140 and/or diastolic BP ≥ 90 mmHg. Among all 494 women, 
19% received antihypertensive treatment. This resulted in an appropriate level of BP (systolic BP 
125±18 and diastolic BP 81±8 mmHg) in late pregnancy (Table 2).   
Of the 95 women receiving antihypertensive treatment, 60% were treated with methyldopa as 
monotherapy, 27% with methyldopa in combination with labetalol and/or slow-release nifedipine 
and 13% with labetalol as monotherapy. In four women with chronic hypertension treated with 
antihypertensive agents before pregnancy, the treatment was stopped in early pregnancy and the BP 
remained below the treatment threshold.  
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Among the 40 women who developed preeclampsia, 55% (n=22) fulfilled our criteria for 
prophylactic aspirin treatment from early pregnancy. Four women were referred in late pregnancy at 
190 gestational days (162-257) and thus aspirin was not given. Among the remaining 18 women, 75 
mg prophylactic aspirin was initiated before 12 gestational weeks in 67% (n=12) during pregnancy.  
Fifty percent of women who developed preeclampsia delivered preterm, while women with 
persistent normotension only delivered preterm in 13% of the cases (p<0.001).  
Birth weight SD-score was similar in the four BP groups. The prevalence of SGA was low and 
similar in the four BP groups (Table 3).  
Univariate logistic regression analysis identified nulliparity, presence of retinopathy, diabetic 
kidney involvement and increasing BP as risk factors for preeclampsia. At the first antenatal visit, 
the presence of diabetic microangiopathy and diastolic BP were independently and positively 
associated with the development of preeclampsia (Table 4) in multivariate analysis. For an increase 
in diastolic BP of 10 mmHg the adjusted odds ratio was 1.72 corresponding to a 72% higher odds of 
developing preeclampsia for an increase in diastolic BP of 10 mmHg.   
Essentially the same risk factors for preeclampsia were found when women with type 1 and type 2 
diabetes were analyzed separately or after exclusion of women with diabetic kidney involvement 
(data not shown). The slightly different recommendations for glycemic control before and after 
2012 did not have an impact on the obtained level of HbA1c in late pregnancy (6.1±0.6 mmol/mol 
vs. 6.0±0.5 mmol/mol, p=0.19).   
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4. Discussion 
In women with pre-existing diabetes, the prevalence of pregnancy-related hypertensive disorders 
was comparable between women with type 1 and type 2 diabetes, given tight glycemic and BP 
control during pregnancy. At the first antenatal visit, diastolic BP and presence of diabetic 
microangiopathy were independent risk factors for preeclampsia.  
The current study is to our knowledge the first study to investigate the prevalence of pregnancy-
related hypertensive disorders and to identify early clinical, potentially modifiable risk factors for 
preeclampsia, in women with pre-existing diabetes treated with tight glycemic and BP control. The 
HbA1c levels achieved in early and late pregnancy are closer to the desired values than the recently 
published national British data [27]. Although the Copenhagen antihypertensive treatment strategy 
recommends initiation of antihypertensive treatment when BP exceeds 135/85 mmHg the majority 
of the women had either systolic BP ≥140 or diastolic BP ≥90 mmHg and were thus diagnosed with 
hypertension at onset of antihypertensive treatment. The Copenhagen antihypertensive treatment 
strategy was therefore not able to prevent gestational hypertension when used in routine care.  
In the current study the overall prevalence of pregnancy-related hypertensive disorders (chronic 
hypertension, gestational hypertension and preeclampsia) was 23%, which is considerably lower 
than the previously published prevalence of 40% reported by Cundy et al [2]. In both the present 
study and the study by Cundy et al (2) the prevalence of hypertensive disorders was comparable in 
type 1 and type 2 diabetes. Additionally, the prevalence of preeclampsia in our cohort was about 
half the prevalence of 17% reported in a recent review including data from 11,518 women with type 
1 diabetes [5]. We speculate that the lower prevalence in the present study may be due to the 
intensive antihypertensive treatment strategy, but a positive influence of tight glycemic control and 
a low prevalence of diabetic microvascular complications cannot be excluded.  
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In our cohort, early diastolic BP was the only potentially modifiable risk factor for preeclampsia. 
Our findings suggest that an increase in diastolic BP of 10 mmHg is associated with an increased 
odds of developing preeclampsia of 72%, which can be valuable and useful for prediction of a 
woman’s risk of developing preeclampsia in a clinical setting. A recent study including 165 women 
with type 1 diabetes, whereof 16 developed preeclampsia, found an association between blood 
pressure and preeclampsia, however this association was mainly driven by the presence of chronic 
hypertension [28]. In our study, including almost 500 pregnant women with diabetes, whereof 40 
developed preeclampsia, the association between diastolic blood pressure and the risk of developing 
preeclampsia remained significant after including presence of chronic hypertension in the 
multivariate logistic regression analysis.  
In women with pre-existing diabetes the positive associations between preeclampsia and nulliparity, 
retinopathy, diabetic kidney involvement and increased BP prior to pregnancy are in accordance 
with other studies [7, 8, 29].  
Glycemic control and pre-pregnancy BMI have previously been described as important risk factors 
for preeclampsia in women with pre-existing diabetes, [29-31]. However, this was not confirmed in 
our study. This might partly be due to the relatively good glycemic control with a high rate of 
women achieving the target values for HbA1c in early and late pregnancy. 
Outside pregnancy, intensive antihypertensive treatment reduces the development and progression 
of elevated albumin excretion and hypertension in patients with diabetes and is used as the golden 
standard treatment [16, 17, 25]. For pregnant women with severe hypertension there is consensus 
that antihypertensive treatment should be given, but there is no consensus regarding the 
management of less severe hypertension during pregnancy [32]. Tight antihypertensive treatment 
during pregnancy, in otherwise healthy women, reduces the prevalence of severe hypertension but 
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may also be associated with intrauterine growth restriction and improved pregnancy outcome has 
not been demonstrated previously [33, 34].   
In the current study, the majority of the women with persistent chronic hypertension and women 
who developed gestational hypertension or preeclampsia were treated according to the Copenhagen 
antihypertensive treatment strategy during pregnancy without an increase in SGA infants. This is in 
line with the findings in a randomized control trial  in women without diabetes where tight BP 
control did not induce SGA infants [35]. The women in our cohort were mainly treated with 
methyldopa, which could also contribute to more appropriate fetal growth compared to labetalol, 
since less growth restriction with methyldopa in comparison to labetalol has been described in 
women without diabetes [36]. Women with type 1 diabetes had a higher prevalence of LGA infants 
and a lower prevalence of SGA infants compared to women with type 2 diabetes. Women with type 
1 diabetes gained almost four kilo grams more during pregnancy, compared to women with type 2 
diabetes. Our center has previously described that gestational weight gain is associated with a 
higher risk of delivering an LGA infant [20-22]. However, the prevalence of smoking and chronic 
hypertension was higher among women with type 2 diabetes and may also play a role in the 
difference in birth weight SD score.  The rate of SGA of 11% in women with type 2 diabetes is 
close to the rate of 10% per definition in the background population. The prevalence of insufficient 
placentation leading to preeclampsia and impaired fetal growth does therefore seem to be low in 
both women with type 1 and type 2 diabetes. 
 
To increase the power of investigating a rare event as preeclampsia we included both women with 
type 1 and type 2 diabetes in this study. A comparable level of glycemic control in early and late 
pregnancy and similar prevalence of microalbuminuria and diabetic nephropathy was seen in the 
two types of diabetes, but other risk factors for preeclampsia as BMI, ethnicity, smoking habits, 
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gestational weight gain and presence of retinopathy was as expected different in the two groups. 
However, diabetes type was not identified as an independent risk factor for preeclampsia in the 
univariate analysis and including the variable “diabetes type” in the multivariate analysis did not 
change the outcome of the analysis. Furthermore, univariate and multivariate logistic regression 
analyses were performed in women with type 1 and type 2 diabetes separately, giving essentially 
the same results in both types of diabetes as the combined cohort. 
 
Strengths of our study are the inclusion of a relatively large, unselected cohort of women with pre-
existing diabetes from a geographically well-defined region and few exclusion criteria. Relevant 
clinical data were prospectively collected in a detailed manner enabling us to study the different 
pregnancy-related hypertensive disorders. Data of this kind can be difficult to obtain in larger 
registry-based studies. Despite including almost 500 women only 40 women developed 
preeclampsia and a potential limitation of this study is that women with type 1 and type 2 diabetes, 
who developed preeclampsia, were analyzed as a combined cohort in order to achieve the highest 
possible power. The generalizability (external validity) of our results is potentially large due to the 
unselected regional recruitment but may be limited due to the single-center design.  
 
Previous studies from our Center applying the Copenhagen antihypertensive treatment strategy have 
suggested a reduction over time in the prevalence of preeclampsia and preterm delivery in women 
with diabetic kidney involvement [15, 17, 18]. Among the women with chronic hypertension in 
early pregnancy, without diabetic kidney involvement, the prevalence of preeclampsia in the present 
study was 11%, which is substantially lower than the prevalence of 24% previously reported in 
women with diabetes and chronic hypertension [2], however numbers are small. Preeclampsia is in 
many cases preceded by a period of increasing blood pressure [9]. Tight antihypertensive treatment 
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in women with diabetes and gestational hypertension might prevent or postpone progression to 
preeclampsia and tight antihypertensive treatment in women with preeclampsia might prevent cases 
with severe hypertension and preterm delivery.  
Since early diastolic BP was the only potentially modifiable risk factor for preeclampsia, it might be 
reasonable to be even more careful in monitoring and treating the BP in pregnant women with pre-
existing diabetes. White coat hypertension is prevalent in pregnancy [37] and outside pregnancy 
home BP measurement is often used to document hypertension and to exclude white coat 
hypertension [38]. In pregnant women with pre-existing diabetes it might be beneficial to initiate 
daily self-monitoring of home BP when elevated office BP is diagnosed, but no studies has 
investigated this strategy so far.  Further studies are needed in women with pre-existing diabetes to 
investigate whether the combination of self-monitoring of home BP and tight antihypertensive 
treatment can reduce the prevalence of preeclampsia and preterm delivery.  
To conclude, in women with pre-existing diabetes receiving tight glycemic and BP control the 
prevalence of pregnancy-related hypertensive disorders, including preeclampsia, was lower than 
previously published. At the first antenatal visit, diastolic BP was the only independent, potentially 
modifiable risk factor for preeclampsia in women with pre-existing diabetes. Further investigations 
of home BP measurement and whether tight antihypertensive treatment can reduce the development 
of preeclampsia in women with pre-existing diabetes are needed.  
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Tables 
Table 1. Maternal characteristics at the first antenatal visit in 307 women with type 1 diabetes and 
187 women with type 2 diabetes 
 All women 
(n=494) 
Type 1 diabetes 
(n=307) 
Type 2 diabetes 
(n=187) p-value 
Duration of diabetes (years) 10.6±8.5* 14.6±8.1 3.9±3.4 <0.001 
Pre-pregnancy BMI (kg/m2) 28.3±11.6* 25.5±4.5 33.0±17.0 <0.001 
Smoking 67 (14%) 29 (9%) 38 (20%) 0.001 
Nordic Caucasian ethnicity 343 (69%) 264 (86%) 79 (42%) <0.001 
Folic acid prior to pregnancy 190 (39%)* 150 (49%) 40 (21%) <0.001 
Nulliparous 231 (47%) 177 (58%) 54 (29%) <0.001 
Gestational age, first visit 
(days) 76±34 67±25 88±43 <0.001 
HbA1c, first visit, % 
(mmol/mol) 
6.9±2.4*  
(50±12) 
6.9±2.3 
(51±10) 
6.8±2.6 
(49±14) 0.51 
Insulin dose, first visit 
(IU/kg/24-h) 0.50±0.3* 0.65±0.2 0.46±0.3
†
 <0.001 
Systolic blood pressure, first 
visit (mmHg) 121±13 120±12 122±14 0.16 
Diastolic blood pressure, 
first visit (mmHg) 77±9 76±8 79±10 0.001 
Normotension at first visit 413 (86%)* 270 (89%) 143 (82%) 0.03 
Chronic hypertension at first 
visit 28 (6%) 10 (3%) 18 (10%) 0.03 
Diabetic retinopathy 136 (27%)* 124 (40%) 12 (6%) <0.001 
Diabetic kidney involvement 38 (8%) 24 (8%) 14 (7%) 0.98 
     Microalbuminuria 
     Diabetic nephropathy 
31 (6%)* 
7 (2%)* 
20 (6%) 
4 (1%) 
11 (6%) 
3 (2%) 
0.90 
0.73 
Numbers are given as mean ±SD, median (range) or number (%). P-value denotes difference across diabetes 
type. *Missing data: Duration of diabetes (n=1), pre-pregnancy BMI (n=3), folic acid prior to pregnancy 
(n=5), HbA1c, first visit (n=3), insulin dose, first visit (n=55), retinopathy before pregnancy, 
microalbuminuria, nephropathy and normotensive without diabetic nephropathy including microalbuminuria 
(n=15). †Numbers are given for those on insulin (n=146).   
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Table 2. Clinical characteristics in late pregnancy and perinatal outcome in 307 women with type 1 
diabetes and 187 women with type 2 diabetes 
 All women 
(n=494) 
Type 1 diabetes 
(n=307) 
Type 2 diabetes 
(n=187) p-value 
Gestational age, last visit (days) 256±33 256±19 257±48 0.74 
HbA1c, last visit, %  
(mmol/mol) 
6.0±0.6* 
(43±6) 
6.1±0.5 
(43±6) 
6.0±0.6 
(42±7) 0.05 
Insulin dose, last visit (IU/Kg/24-h) 0.94±0.6* 0.95±0.4 1.15±0.7† 0.63 
Systolic blood pressure, last visit 
(mmHg) 
 
125±18 125±20 123±13 0.20 
Diastolic blood pressure, last visit 
(mmHg) 81±8 81±8 81±8 0.99 
Gestational hypertension 39 (8%) 27 (9%) 12 (6%) 0.34 
Preeclampsia 40 (8%) 27 (9%) 13 (7%) 0.45 
Antihypertensive treatment  95 (19%)* 56 (18%) 39 (21%) 0.58 
Total gestational weight gain (kg) 14.0±6.5* 15.2±5.9 11.5±6.8 <0.001 
Gestational age at delivery (days) 265 (186-287) 264 (193-287) 265 (186-282) 0.47 
Preterm delivery  83 (17%) 53(17%) 30 (16%) 0.72 
Cesarean section 216 (44%) 136 (44%) 80 (43%) 0.81 
Offspring birth weight (g) 3,416±609 3,501±542 3,277±684 <0.001 
Offspring birth weight SD score 0.78±1.6 1.04±1.4 0.36±1.8 <0.001 
Large for gestational age infants 184 (37%) 130 (42%) 54 (29%) 0.003 
Small for gestational age infants 34 (7%) 14 (5%) 20 (11%) 0.009 
Numbers are given as mean ±SD, median (range) or number (%). P-value denotes difference across diabetes 
type by independent t-test, Mann Whitney test or Chi-square test. *Missing data: HbA1c, last visit (n=5), 
Insulin dose, last visit (n=84), antihypertensive treatment given (n=1), total gestational weight gain (n=6). † 
Numbers are given for those on insulin (n=143).    
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Table 3. Clinical data and pregnancy outcome in relation to presence of pregnancy-related 
hypertensive disorders at the end of pregnancy in 494 women with type 1 or type 2 diabetes 
 Persistent 
normotension 
 
Persistent 
chronic 
hypertension 
 
Gestational 
hypertension 
 
Preeclampsia 
 
p-value 
Total 379 (77%) 36 (7%) 39 (8%) 40 (8%)  
     Type 1 
     Type 2 
235 (76%) 
144 (77%) 
18 (6%)  
18 (10%) 
27 (9%)  
12 (6%) 
27 (9%)  
13 (7%) 
 
 
 
Nulliparous 
 
168 (44%) 
 
15 (42%) 
 
21 (54%) 
 
27 (68%)a 
 
0.03 
Pre-pregnancy BMI (kg/m2) 27.9±12.6* 31.4±7.3 28.6±7.2 29.8±8.4 0.28 
HbA1c, first visit % 
(mmol/mol) 
6.9±2.7* 
(50±12) 
6.6±1.1 
(49±12) 
6.9±1.2 
(52±13) 
6.8±1.0 
(51±11) 
0.96 
(0.56) 
HbA1c, last visit % (mmol/mol) 6.0±0.6* (42±6) 
5.9±0.6 
(41±7) 
6.1±0.5 
(43±5) 
6.1±0.5* 
(43±5) 
0.58 
(0.74) 
Systolic blood pressure, first 
visit (mmHg) 
119±11* 135±14 124±11 129±15a <0.001 
Diastolic blood pressure, first 
visit (mmHg) 
76±7* 87±11 79±7 84±12a <0.001 
Normotensive at first visit  353 (97%)* 0 (0%) 36 (95%)* 24 (60%)a,b,c <0.001 
Chronic hypertension at first 
visit  0 (0%) 25 (69%) 0 (0%) 3 (8%)
a,b
 <0.001 
Diabetic kidney involvement 12 (3%)* 11 (31%) 2 (5%)* 13 (32%)a,c <0.001 
Retinopathy, first visit 86 (23%) 15 (42%) 13 (33%) 22 (55%)
a <0.001 
Antihypertensive treatment  2 (0.5%)* 32 (89%) 28 (72%) 33 (83%)a <0.001 
Gestational age at delivery 
(days) 
266  
(193-284) 
263  
(203-287) 
262  
(201-274) 
258  
(186-275)a,b,c <0.001 
Preterm delivery  51 (13%) 4 (11%) 8 (20%) 20 (50%)a,b,c <0.001 
Cesarean section 155 (41%) 22 (61%) 17 (44%) 22 (55%) 0.12 
Offspring birth weight (g) 3,481±569 3,158±745 3,261±614 3,190±715 <0.001 
Offspring birth weight SD score 0.84±1.6 0.25±1.7 0.64±1.4 0.80±1.6 0.19 
Large for gestational age infants 149 (39%) 8 (22%) 11 (28%) 16 (40%) 0.13 
Small for gestational age infants 23 (6%) 6 (17%) 1 (3%) 4 (10%) 0.06 
Numbers are given as mean ±SD, median (range) or number (%). P-value denotes difference across severity 
of hypertension by ANOVA, Kruskall Wallis test or Chi-square test. *Missing data: Pre-pregnancy BMI 
(n=3), HbA1c, first visit (n=3), HbA1c last visit (n=7, n=2), systolic BP and diastolic BP first visit (n=2), 
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diabetic nephropathy including microalbuminuria and normotensive at first visit without diabetic 
nephropathy or microalbuminuria (n=14, n=1), antihypertensive treatment given (n=1).  
a: p-value <0.017. Denotes difference between persisting normotension and preeclampsia 
b: p-value <0.017. Denotes difference between chronic hypertension and preeclampsia 
c: p-value <0.017. Denotes difference between gestational hypertension and preeclampsia 
The p-value above (<0.017) corresponds to the significance level used, corrected for multiple testing by 
using the Bonferroni method (0.05/3=0.017).  
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Table 4. Risk factors for preeclampsia in 494 women with type 1 or type 2 diabetes illustrated by 
univariate and multivariate logistic regression analysis 
 
Univariate logistic regression analysis 
 
Independent variable Unadjusted OR 95% CI p-value 
Type 1 diabetes (yes/no) 1.38 0.83 - 2.31 0.22 
Duration of diabetes (years) 1.03 0.99 - 1.07 0.09 
Nordic Caucasian ethnicity (yes/no) 0.46 0.20 - 1.06 0.07 
Pre-pregnancy BMI (kg/m2) 1.01 0.99 - 1.03 0.42 
HbA1c, first visit, (%) 0.99 0.86 - 1.15 0.93 
Systolic BP, first visit (mmHg) 1.05 1.03 - 1.08 <0.001 
Diastolic BP, first visit (mmHg) 1.08 1.04 - 1.11 <0.001 
Nulliparous 2.54 1.28 - 5.06 <0.01 
Chronic hypertension at first visit 2.90 1.24 - 6.77 0.014 
Retinopathy at first visit 3.15 1.63 - 6.07 0.001 
Diabetic kidney involvement 7.97 3.67 - 17.31 <0.001 
Diabetic microangiopathy‡ 5.38 2.70 - 10.80 <0.001 
Multivariate logistic regression analysis 
 
Independent variable                              Adjusted OR                     95% CI                              p-value 
Nulliparous 2.06 0.99 - 4.27 0.05 
Diabetic microangiopathy 4.35 2.12 - 8.93 <0.001 
Systolic BP, first visit (per 10 mmHg) 1.19 0.82 - 1.72 0.35 
Diastolic BP, first visit (per 10 mmHg) 1.72 1.05 - 2.82 0.03 
‡: Presence of one or more of the following: microalbuminuria, diabetic nephropathy and/or retinopathy.  
 
 
 
Highlights 
• One out of four women with diabetes had hypertensive disorders during pregnancy. 
• Diastolic blood pressure in early pregnancy is an important risk factor for preeclampsia  
Intensified monitoring and treatment of the blood pressure should be considered  
 
 
